StockData
Septerna, Inc. logo

Septerna, Inc. (SEPN) shareholders

SEPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30165% above fair value
$40.02−1.65 (-3.96%)

Close on Nov 17, 2026Market cap $1.87BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
47M of 47M shares
Institutional holders
154
48 new, 16 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 40 sales
Net sold $80.88M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Trv Gp V, LLC
Joint filing with Third Rock Ventures V, L.P. (14.00%), Third Rock Ventures GP V, L.P. (14.00%) and 3 more
6,215,59114.00%13G (passive) amendmentMar 31, 2025
Peter Kolchinsky
Joint filing with RA Capital Management, L.P. (11.80%), Rajeev Shah (11.80%) and 1 more
5,525,32411.80%13D (active) amendmentAug 12, 2026
Driehaus Capital Management LLC4,433,0589.83%13G (passive) amendmentJun 30, 2026
Lampert Mark N
Joint filing with Bvf Partners L P/Il (9.90%), Bvf Inc/Il (9.90%) and 3 more
4,396,1249.90%13G (passive) amendmentMar 31, 2025
Samsara BioCapital, L.P.
Joint filing with Samsara BioCapital GP, LLC (6.20%), Srinivas Akkaraju (6.20%)
2,768,5206.20%13G (passive)Oct 28, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SEPNValueChange% of portfolio
Ra Capital Management, L.P.6,995,85814.99%$234.29M–2.04%
Trv Gp V, LLC6,215,59113.32%$208.16M–41.78%
Driehaus Capital Management LLC4,433,0589.50%$148.46M+37,4860.86%
Trv Gp Vi, LLC4,211,6599.02%$141.05M–60.72%
Samsara BioCapital, LLC3,149,1286.75%$105.46M–8.66%
Goldman Sachs Group Inc3,062,7666.56%$102.57M+156,3390.01%
BlackRock, Inc.1,932,0884.14%$64.71M+109,9140.00%
Siren, L.L.C.1,900,0004.07%$63.63M−100,0001.29%
Avoro Capital Advisors LLC1,337,5002.87%$44.79M–0.40%
Jupiter Topco LLC1,307,5002.80%$43.72MNew0.02%
Vanguard Capital Management LLC1,221,6732.62%$40.91M+24,7110.00%
Primecap Management Co/Ca/1,167,3822.50%$39.10M+118,5480.02%
First Light Asset Management, LLC963,2602.06%$32.26M+230,4001.96%
ADAR1 Capital Management, LLC940,7472.02%$31.51M−149,0711.44%
Geode Capital Management, LLC679,1631.46%$22.75M+34,0170.00%
State Street Corp652,6301.40%$21.86M+21,1830.00%
Loomis Sayles & Co L P624,7521.34%$20.92MNew0.03%
Casdin Capital, LLC553,2681.19%$18.53M–0.93%
Catalio Capital Management, LP536,1521.15%$17.96M+241,7923.37%
Algert Global LLC397,4870.85%$13.31M+376,4520.16%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202615447M100.0%48 / 4932 / 165M3M
Q1 202612446M98.4%28 / 4430 / 245M3M
Q4 202512246M97.7%45 / 3127 / 55M4M
Q3 20258245M95.5%10 / 3216 / 162M2M
Q2 20258944M95.2%25 / 3119 / 64M5M
Q1 20257145M97.0%20 / 2512 / 198M7M
Q4 20247144M94.5%71 / 00 / 044M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

169 funds held SEPN in Q2 2026, 44% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of SEPNValue% of fundAs of
Vanguard Total Stock Market Index Fund927,6651.99%$31.07M0.00%Jun 30, 2026
PRIMECAP Odyssey Aggressive Growth Fund824,5821.77%$28.41M0.38%Jul 31, 2026
iShares Russell 2000 ETF578,5231.24%$19.37M0.02%Jun 30, 2026
Driehaus Small Cap Growth Fund417,8590.90%$13.99M0.87%Jun 30, 2026
Loomis Sayles Small Cap Growth Fund338,5790.73%$11.34M0.50%Jun 30, 2026
Vanguard Extended Market Index Fund261,5470.56%$8.76M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund242,4560.52%$8.35M0.02%Jul 31, 2026
iShares Biotechnology ETF192,6450.41%$6.45M0.07%Jun 30, 2026
Driehaus Micro Cap Growth Fund158,2720.34%$5.30M0.89%Jun 30, 2026
iShares Russell 2000 Growth ETF138,8340.30%$4.65M0.03%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF126,6960.27%$4.24M0.99%Jun 30, 2026
Fidelity Extended Market Index Fund116,9000.25%$3.53M0.01%May 31, 2026
Column Small Cap Select Fund110,8860.24%$3.35M0.18%May 31, 2026
Vanguard Russell 2000 Index Fund109,7700.24%$3.32M0.02%May 31, 2026
Schwab U.S. Small-Cap ETF108,1280.23%$3.27M0.01%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jeffrey FinerChief Executive Officer, Director833,9091.79%Nov 16, 2026
Elizabeth BhattPresident and COO174,2090.37%Oct 19, 2026
Rajiv PatniChief Medical Officer––Sep 10, 2026
Daniel D. LongSVP, Drug Discovery96,4120.21%Sep 3, 2026
Samira ShaikhlyChief People Officer7930.00%Jun 30, 2026
Uwe KleinSVP, Biological Sciences119,9120.26%Feb 10, 2026
Jae B. KimChief Medical Officer––Feb 10, 2026
Mark Andrew WilsonChief Legal Officer––Feb 10, 2026
Gil M. LabrucherieChief Financial Officer40,0000.09%Feb 10, 2026
Alan EzekowitzDirector35,6000.08%Nov 13, 2026
Capital Healthcare Fund LP RADirector, 10% owner––Aug 14, 2026
Peter KolchinskyDirector, 10% owner––Aug 14, 2026
RA Capital Nexus Fund III, L.P.Director––Aug 14, 2026
Rajeev M. ShahDirector, 10% owner725,4431.55%Aug 14, 2026
Ra Capital Management, L.P.Director, 10% owner––Aug 14, 2026
Shalini SharpDirector––Jun 30, 2026
Keith Michael GottesdienerDirector––Jun 30, 2026
Bernard CoulieDirector––Jun 30, 2026
Jeffrey K. TongDirector––Jun 30, 2026
Abraham BassanDirector––Jun 30, 2026
Jake SimsonDirector––Jun 30, 2026
Third Rock Ventures GP VI, L.P.10% owner10,280,19122.02%Aug 14, 2026
Trv Gp V, Llc10% owner12,241,00326.22%Aug 14, 2026
Third Rock Ventures VI, L.P.10% owner––Aug 14, 2026
Third Rock Ventures GP V, LP10% owner10,427,25022.34%Aug 14, 2026
Trv Gp Vi, Llc10% owner––Aug 14, 2026
Third Rock Ventures V, L.P.10% owner––Aug 14, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jeffrey Finer
Chief Executive Officer, Director
Nov 12, 2026Sale(10b5-1 plan)−1,977$46.16$91.26K833,909
Jeffrey Finer
Chief Executive Officer, Director
Nov 12, 2026Sale(10b5-1 plan)−2,823$45.28$127.81K835,886
Jeffrey Finer
Chief Executive Officer, Director
Nov 12, 2026Sale(10b5-1 plan)−2,800$44.23$123.83K838,709
Jeffrey Finer
Chief Executive Officer, Director
Nov 12, 2026Sale(10b5-1 plan)−5,300$43.10$228.41K841,509
Jeffrey Finer
Chief Executive Officer, Director
Nov 12, 2026Sale(10b5-1 plan)−5,600$42.09$235.70K846,809
Jeffrey Finer
Chief Executive Officer, Director
Nov 12, 2026Option exercise+18,500$2.76$51.06K852,409
Alan Ezekowitz
Director
Nov 11, 2026Sale(10b5-1 plan)−1,055$51.90$54.75K35,600
Alan Ezekowitz
Director
Nov 11, 2026Sale(10b5-1 plan)−2,013$50.90$102.46K36,655
Alan Ezekowitz
Director
Nov 11, 2026Sale(10b5-1 plan)−4,175$49.65$207.27K38,668
Alan Ezekowitz
Director
Nov 11, 2026Sale(10b5-1 plan)−31,572$48.70$1.54M42,843
Alan Ezekowitz
Director
Nov 11, 2026Sale(10b5-1 plan)−22,865$47.78$1.09M74,415
Alan Ezekowitz
Director
Nov 11, 2026Sale(10b5-1 plan)−13,201$47.01$620.60K97,280
Alan Ezekowitz
Director
Nov 11, 2026Sale(10b5-1 plan)−6,939$46.01$319.23K110,481
Elizabeth Bhatt
President and COO
Oct 15, 2026Sale(10b5-1 plan)−2,906$37.61$109.31K174,209
Elizabeth Bhatt
President and COO
Oct 15, 2026Sale(10b5-1 plan)−1,094$36.87$40.34K177,115
Elizabeth Bhatt
President and COO
Oct 15, 2026Option exercise+4,000$6.81$27.24K178,209
Daniel D. Long
SVP, Drug Discovery
Sep 1, 2026Sale(10b5-1 plan)−3,333$37.83$126.09K96,412
Daniel D. Long
SVP, Drug Discovery
Sep 1, 2026Option exercise+3,333$2.76$9.20K99,745
Rajeev M. Shah
Director, 10% owner
Aug 12, 2026Sale−746,500$42.50$31.73M725,443
Rajeev M. Shah
Director, 10% owner
Aug 12, 2026Sale−746,500$42.50$31.73M4,777,415
Third Rock Ventures GP VI, L.P.
10% owner
Aug 12, 2026Sale(10b5-1 plan)+147,059$50.27$7.39M6,068,532
Third Rock Ventures GP VI, L.P.
10% owner
Aug 12, 2026Sale(10b5-1 plan)+141$51.08$7.20K6,068,391
Elizabeth Bhatt
President and COO
Aug 11, 2026Option exercise+6,319$2.76$17.44K199,209
Elizabeth Bhatt
President and COO
Aug 11, 2026Sale(10b5-1 plan)−25,000$44.00$1.10M174,209
Elizabeth Bhatt
President and COO
Aug 11, 2026Option exercise+18,681$6.81$127.22K192,890
Daniel D. Long
SVP, Drug Discovery
Aug 3, 2026Option exercise+1,518$2.76$4.19K99,746
Daniel D. Long
SVP, Drug Discovery
Aug 3, 2026Option exercise+1,816$2.76$5.01K98,228
Daniel D. Long
SVP, Drug Discovery
Aug 3, 2026Sale(10b5-1 plan)−1,000$33.98$33.98K98,746
Daniel D. Long
SVP, Drug Discovery
Aug 3, 2026Sale(10b5-1 plan)−2,334$34.68$80.94K96,412
Elizabeth Bhatt
President and COO
Jul 15, 2026Option exercise+4,000$6.81$27.24K178,209
Elizabeth Bhatt
President and COO
Jul 15, 2026Sale(10b5-1 plan)−4,000$33.99$135.96K174,209
Daniel D. Long
SVP, Drug Discovery
Jul 1, 2026Sale(10b5-1 plan)−2,100$34.10$71.61K97,645
Daniel D. Long
SVP, Drug Discovery
Jul 1, 2026Option exercise+3,333$2.76$9.20K99,745
Daniel D. Long
SVP, Drug Discovery
Jul 1, 2026Sale(10b5-1 plan)−1,233$34.81$42.92K96,412
Samira Shaikhly
Chief People Officer
Jun 29, 2026Sale(10b5-1 plan)−2,178$35.18$76.62K793
Samira Shaikhly
Chief People Officer
Jun 29, 2026Option exercise+2,178$6.81$14.83K2,971
Daniel D. Long
SVP, Drug Discovery
Jun 22, 2026Option exercise+4,471$11.70$52.31K111,412
Daniel D. Long
SVP, Drug Discovery
Jun 22, 2026Sale(10b5-1 plan)−8,000$35.10$280.80K103,412
Daniel D. Long
SVP, Drug Discovery
Jun 22, 2026Sale(10b5-1 plan)−7,000$35.97$251.79K96,412
Daniel D. Long
SVP, Drug Discovery
Jun 22, 2026Option exercise+10,529$2.76$29.06K106,941
Samira Shaikhly
Chief People Officer
Jun 12, 2026Sale(10b5-1 plan)−6,250$35.08$219.25K793
Samira Shaikhly
Chief People Officer
Jun 12, 2026Option exercise+6,250$11.70$73.13K7,043
Samira Shaikhly
Chief People Officer
Jun 1, 2026Sale(10b5-1 plan)−1,346$28.79$38.75K3,682
Samira Shaikhly
Chief People Officer
Jun 1, 2026Option exercise+4,355$1.55$6.75K5,148
Samira Shaikhly
Chief People Officer
Jun 1, 2026Option exercise+943$2.76$2.60K6,091
Samira Shaikhly
Chief People Officer
Jun 1, 2026Option exercise+637$2.76$1.76K6,728
Samira Shaikhly
Chief People Officer
Jun 1, 2026Sale(10b5-1 plan)−2,889$29.66$85.69K793
Samira Shaikhly
Chief People Officer
Jun 1, 2026Sale(10b5-1 plan)−1,700$27.78$47.23K5,028
Samira Shaikhly
Chief People Officer
May 26, 2026Option exercise+11,798$6.81$80.34K12,591
Samira Shaikhly
Chief People Officer
May 26, 2026Sale(10b5-1 plan)−11,798$30.06$354.65K793
Elizabeth Bhatt
President and COO
Apr 15, 2026Sale(10b5-1 plan)−1,101$25.24$27.79K174,535
Elizabeth Bhatt
President and COO
Apr 15, 2026Option exercise+4,000$6.81$27.24K178,209
Elizabeth Bhatt
President and COO
Apr 15, 2026Sale(10b5-1 plan)−326$25.86$8.43K174,209
Elizabeth Bhatt
President and COO
Apr 15, 2026Sale(10b5-1 plan)−2,573$23.76$61.13K175,636
Samira Shaikhly
Chief People Officer
Mar 2, 2026Option exercise+53,714$1.55$83.26K54,507
Samira Shaikhly
Chief People Officer
Mar 2, 2026Option exercise+11,638$2.76$32.12K66,145
Samira Shaikhly
Chief People Officer
Mar 2, 2026Option exercise+5,101$2.76$14.08K71,246
Samira Shaikhly
Chief People Officer
Mar 2, 2026Sale(10b5-1 plan)−4,090$27.51$112.52K67,156
Samira Shaikhly
Chief People Officer
Mar 2, 2026Sale(10b5-1 plan)−66,363$28.14$1.87M793
Elizabeth Bhatt
President and COO
Feb 18, 2026Option exercise+4,000$6.81$27.24K178,209

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
9.97%
3M shares short
Days to cover
11.9
At 0M shares a day
Change since last report
-4.8%
From 4M shares
Short volume, 20 days
63.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Septerna's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,120 shares on Oct 14, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Daniel D. Long
Officer
Oct 1, 202610,001$391.34KOct 1, 2026Exercise of Stock Options
Samira Shaikhly
Officer
Oct 1, 202612,592$492.72KOct 1, 2026Exercise of Stock Options
RA Capital Nexus Fund III, L.P.
Affiliate
Aug 12, 2026746,500$35.97MAug 12, 2026IPO / Private round
Capital Healthcare Fund LP RA
affiliate
Aug 12, 2026746,500$35.97MAug 12, 2026IPO
Third Rock Ventures V, L.P.
10% Stockholder
Aug 12, 2026147,200$7.51MAug 12, 2026Original Issuance
Elizabeth Bhatt
Officer
Aug 11, 202629,000$1.13MAug 11, 2026Exercise of Stock Options
Elizabeth Bhatt
Officer
Jul 15, 20264,000$138.16KJul 15, 2026Exercise of Stock Options
Jae B. Kim
Officer
Jun 26, 20262,438$89.24KJun 26, 2026Employee Stock Purchase Plan
Jae B. Kim
Officer
Jun 22, 202694,339$3.33MJun 22, 2026Stock Option Exercise
Daniel D. Long
Officer
Jun 22, 202625,000$904.25KJun 22, 2026Exercise of Stock Options
Samira Shaikhly
Officer
Jun 12, 20268,428$286.80KJun 12, 2026Exercise of Stock Options
Samira Shaikhly
Officer
May 26, 202611,798$334.59KMay 26, 2026Exercise of Stock Options
Samira Shaikhly
Officer
Mar 2, 202676,388$2.22MMar 2, 2026Exercise of Stock Options
Elizabeth Bhatt
Officer
Feb 18, 20268,000$242.40KFeb 18, 2026Exercise of Stock Options
Daniel D. Long
Officer
Nov 10, 20253,501$63.22KNov 10, 2025Employee Stock Purchase Plan

See a number that looks wrong?